Chugai Pharma USA
9
1
1
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 9 trials
100.0%
+13.5% vs industry average
22%
2 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment
Role: collaborator
RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer
Role: collaborator
Two Different Collection Sets for Peripheral Blood Progenitor Cell Apheresis With Spectra Optia®
Role: collaborator
Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial
Role: collaborator
Elderly Independent Patients With Non Small Cell Lung Cancer (NSCLC)
Role: collaborator
A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment
Role: collaborator
Safety and Effectiveness of an Investigational Agent (GM-611) in Patients With Diabetic Gastroparesis
Role: lead
A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Vessel Re-Closure (Restenosis) in Stented Vessels.
Role: lead
An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast Cancer
Role: lead
All 9 trials loaded